Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib ; day:5 ; month:1 ; year:2023 ; pages:1-12
Cancer immunology immunotherapy ; (5.1.2023), 1-12
- Creator
-
Häselbarth, Lukas
Karow, Axel
Mentz, Kristin
Böttcher, Martin
Roche-Lancaster, Oisin
Krumbholz, Manuela
Jitschin, Regina
Mougiakakos, Dimitrios
Metzler, Markus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-022-03361-8
- URN
-
urn:nbn:de:101:1-2023031421025031770097
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Häselbarth, Lukas
- Karow, Axel
- Mentz, Kristin
- Böttcher, Martin
- Roche-Lancaster, Oisin
- Krumbholz, Manuela
- Jitschin, Regina
- Mougiakakos, Dimitrios
- Metzler, Markus
- SpringerLink (Online service)
Other Objects (12)
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Die Wirkung der Rezeptortyrosinkinase-Inhibitoren Dasatinib, Nilotinib und Imatinib auf die Proliferation von Fibroblasten im Zellkulturmodell
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BCR-ABL-Mutationsanalytik im Rahmen der Zweitlinientherapie mit Dasatinib nach Imatinib-Versagen von Patienten mit chronischer myeloischer Leukämie
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Die Wirkung der Rezeptortyrosinkinase-Inhibitoren Dasatinib, Nilotinib und Imatinib auf die Proliferation von Fibroblasten im Zellkulturmodell
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BCR-ABL-Mutationsanalytik im Rahmen der Zweitlinientherapie mit Dasatinib nach Imatinib-Versagen von Patienten mit chronischer myeloischer Leukämie
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
Die Wirkung der Rezeptortyrosinkinase-Inhibitoren Dasatinib, Nilotinib und Imatinib auf die Proliferation von Fibroblasten im Zellkulturmodell
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BCR-ABL-Mutationsanalytik im Rahmen der Zweitlinientherapie mit Dasatinib nach Imatinib-Versagen von Patienten mit chronischer myeloischer Leukämie
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China